| Market Capitalization (Millions $) |
8,564 |
| Shares
Outstanding (Millions) |
157 |
| Employees |
399 |
| Revenues (TTM) (Millions $) |
800 |
| Net Income (TTM) (Millions $) |
441 |
| Cash Flow (TTM) (Millions $) |
313 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
TG Therapeutics Inc. is a publicly-traded biopharmaceutical company based in New York City, focused on the development of innovative therapies for the treatment of cancer and autoimmune diseases. The company's pipeline consists of multiple product candidates, including small molecule inhibitors and monoclonal antibodies.
One of the company's most advanced product candidates is umbralisib, an oral inhibitor of phosphoinositide 3-kinase (PI3K) delta and casein kinase-1 epsilon (CK1e) that is being evaluated in clinical trials for the treatment of hematologic malignancies and solid tumors. The drug has demonstrated promising anti-tumor activity in early-phase studies and is currently in phase III development for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
TG Therapeutics also has a pipeline of monoclonal antibodies targeting B-cell-specific proteins, including ublituximab, a glycoengineered anti-CD20 monoclonal antibody that targets the same protein as rituximab but has greater efficacy and reduced side effects. This drug, in combination with umbralisib, has shown potential in a phase III clinical trial for relapsed or refractory CLL/SLL.
The company's other product candidates include TG-1501, a monoclonal antibody that targets a B-cell receptor signaling protein, and TG-1701, a next-generation BTK inhibitor that is in preclinical development.
TG Therapeutics is also exploring the potential of its product candidates in other indications, such as multiple sclerosis and inflammatory bowel disease.
In addition to its drug development efforts, TG Therapeutics has also entered into partnerships and collaborations with other companies, academic institutions, and research organizations to advance the development of its product candidates and expand its pipeline.
Overall, TG Therapeutics is a cutting-edge biopharmaceutical company focused on developing innovative therapies for the treatment of cancer and autoimmune diseases. With a strong pipeline of product candidates and ongoing clinical trials, the company has the potential to make a significant impact on patient outcomes in these therapeutic areas.
Company Address: 3020 Carrington Mill Blvd, Suite 475 Morrisville 27560 NC
Company Phone Number: 575-8489 Stock Exchange / Ticker: NASDAQ TGTX
|
0.13% 
98.24 %